by Leanne Talbot | May 28, 2021
Neuroendocrine Cancer UK is supporting Skin Cancer Awareness Month. Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer, primarily affecting older patients, and thought to arise from the cutaneous Merkel cell, a neuroendocrine cell. The exact cause of... by Leanne Talbot | May 20, 2021
Neuroendocrine Cancer UK is supporting Skin Cancer Awareness Month. Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer, primarily affecting older patients, and thought to arise from the cutaneous Merkel cell, a neuroendocrine cell. The exact cause... by Leanne Talbot | Apr 21, 2021
21st APRIL NICE APPROVES AVELUMAB Neuroendocrine Cancer UK is delighted to share with you NICE’s approval of Avelumab as a first line therapy option in metastatic MCC. Avelumab is now recommended as an option for treating metastatic Merkel cell carcinoma in adults... by Leanne Talbot | Apr 20, 2021
Yesterday, Monday April 19th, NICE launched their 2021-2026 strategy ” a vision for the future”. According to NICE – Public and patients will see: – An interactive guideline structure that facilitates links to the underpinning evidence and... by Leanne Talbot | Mar 29, 2021
The NICE Supporting adult carers quality standard (QS 2021) has now been published. This quality standard covers the provision of support for adults aged 18 or over who provide unpaid care for 1 or more people aged 16 or over with health and social care needs. It... 
